GAT229
GAT229 is a CB1 positive allosteric modulator (PAM) that effectively reduces intraocular pressure (IOP) in high IOP mouse models and enhances CB1 receptor-mediated IOP-lowering effects. A 0.2% GAT229 solution or 10 mg/kg of GAT229 alone significantly reduces IOP. GAT229 is promising for research related to glaucoma and elevated intraocular pressure[1].
Product Specifications
CAS Number
889860-85-9
UNSPSC
12352005
Target
Cannabinoid Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/gat229.html
Smiles
O=[N+](C[C@H](C1=C(C2=CC=CC=C2)NC3=C1C=CC=C3)C4=CC=CC=C4)[O-]
Molecular Formula
C22H18N2O2
Molecular Weight
342.39
References & Citations
[1]Cairns EA, et al. The In Vivo Effects of the CB1-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice. J Ocul Pharmacol Ther. 2017 Oct;33 (8) :582-590.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TRC-B592140-10MG 10 mg
Bis(cyclopentadienyl)zirconium Chloride Hydride
Sign In for Pricing
View Details 
BNCB0788-100 1x 100 µL
MART-1 / Melan-A (MLANA/788), Biotin conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
TRC-D185007-2.5MG 2.5 mg
1,2-Dilinoleoyl-3-tert-butyldiphenylsilyl Glycerol-d5
Sign In for Pricing
View Details 